{"PubmedArticle": [{"MedlineCitation": {"OtherID": [], "SpaceFlightMission": [], "KeywordList": [["Anti-vascular endothelial growth factor (VEGF) therapies", "BCVA", "EVEREST\u00a0II", "Long-term outcomes", "Polypoidal choroidal vasculopathy"]], "CitationSubset": [], "InvestigatorList": [], "OtherAbstract": [], "GeneralNote": [], "PMID": "38308746", "DateRevised": {"Year": "2024", "Month": "07", "Day": "08"}, "Article": {"Language": ["eng"], "ArticleDate": [{"Year": "2024", "Month": "02", "Day": "03"}], "ELocationID": ["10.1007/s40123-024-00888-0"], "Journal": {"ISSN": "2193-8245", "JournalIssue": {"Volume": "13", "Issue": "4", "PubDate": {"Year": "2024", "Month": "Apr"}}, "Title": "Ophthalmology and therapy", "ISOAbbreviation": "Ophthalmol Ther"}, "ArticleTitle": "Six-Year Outcomes in Subjects with Polypoidal Choroidal Vasculopathy in the EVEREST\u00a0II Study.", "Pagination": {"StartPage": "935", "EndPage": "954", "MedlinePgn": "935-954"}, "Abstract": {"AbstractText": ["The EVEREST\u00a0II study previously reported that intravitreally administered ranibizumab (IVR) combined with photodynamic therapy (PDT) achieved superior visual gain and polypoidal lesion closure compared to IVR alone in patients with polypoidal choroidal vasculopathy (PCV). This follow-up study reports the long-term outcomes 6\u00a0years after initiation of the EVEREST\u00a0II study.", "This is a non-interventional cohort study of 90 patients with PCV from 16 international trial sites who originally completed the EVEREST\u00a0II study. The long-term outcomes were assessed during a recall visit at about 6\u00a0years from commencement of EVEREST\u00a0II.", "The monotherapy and combination groups contained 41 and 49 participants, respectively. The change in best-corrected visual acuity (BCVA) from baseline to year\u00a06 was not different between the monotherapy and combination groups; - 7.4\u2009\u00b1\u200923.0 versus - 6.1\u2009\u00b1\u200922.4 letters, respectively. The combination group had greater central subfield thickness (CST) reduction compared to the monotherapy group at year\u00a06 (- 179.9 vs - 74.2\u00a0\u00b5m, p\u2009=\u20090.011). Fewer eyes had subretinal fluid (SRF)/intraretinal fluid (IRF) in the combination versus monotherapy group at year\u00a06 (35.4% vs 57.5%, p\u2009=\u20090.032). Factors associated with BCVA at year\u00a06 include BCVA (year\u00a02), CST (year\u00a02), presence of SRF/IRF at year\u00a02, and number of anti-VEGF treatments (years\u00a02-6). Factors associated with presence of SRF/IRF at year\u00a06 include combination arm (OR 0.45, p\u2009=\u20090.033), BCVA (year\u00a02) (OR 1.53, p\u2009=\u20090.046), and presence of SRF/IRF (year\u00a02) (OR 2.59, p\u2009=\u20090.042).", "At 6\u00a0years following the EVEREST\u00a0II study, one-third of participants still maintained good vision. As most participants continued to require treatment after exiting the initial trial, ongoing monitoring and re-treatment regardless of polypoidal lesion status are necessary in PCV.", "ClinicalTrials.gov identifier, NCT01846273."], "CopyrightInformation": "\u00a9 2024. The Author(s)."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Singapore Eye Research Institute, Singapore National Eye Centre, 11 Third Hospital Avenue, Singapore, 168751, Singapore."}], "LastName": "Teo", "ForeName": "Kelvin Yi Chong", "Initials": "KYC"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Ophthalmology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea."}], "LastName": "Park", "ForeName": "Kyu-Hyung", "Initials": "KH"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Hospital Selayang, Batu Caves, Selangor, Malaysia."}], "LastName": "Ngah", "ForeName": "Nor Fariza", "Initials": "NF"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Ophthalmology, Taipei Veterans General Hospital, School of Medicine, National Yang Ming Chiao Yung University, 201 Shih-Pai Road, Taipei, 112, Taiwan."}], "LastName": "Chen", "ForeName": "Shih-Jen", "Initials": "SJ"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Ophthalmology, College of Medicine, Rangsit University, Rajavithi Hospital, Bangkok, Thailand."}], "LastName": "Ruamviboonsuk", "ForeName": "Paisan", "Initials": "P"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Ophthalmology, Nihon University School of Medicine, Tokyo, Japan."}], "LastName": "Mori", "ForeName": "Ryusaburo", "Initials": "R"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Miyake Eye Hospital Ophthalmology, Ozone, Kita-ku, Nagoya City, Japan."}], "LastName": "Kondo", "ForeName": "Nagako", "Initials": "N"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Nune Eye Hospital, Seoul, South Korea."}], "LastName": "Lee", "ForeName": "Won Ki", "Initials": "WK"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Tan Tock Seng Hospital, National Healthcare Group Eye Institute, Singapore, Singapore."}], "LastName": "Rajagopalan", "ForeName": "Rajesh", "Initials": "R"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "The University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan."}], "LastName": "Obata", "ForeName": "Ryo", "Initials": "R"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Hong Kong Sanatorium and Hospital, Happy Valley, Hong Kong."}], "LastName": "Wong", "ForeName": "Ian Y H", "Initials": "IYH"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "National University Hospital, Singapore, Singapore."}], "LastName": "Chee", "ForeName": "Caroline", "Initials": "C"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Nagoya University Hospital, Nagoya City, Aichi, Japan."}], "LastName": "Terasaki", "ForeName": "Hiroko", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Fukushima Medical University Hospital, Fukushima City, Fukushima, Japan."}], "LastName": "Sekiryu", "ForeName": "Tetsuju", "Initials": "T"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan."}], "LastName": "Chen", "ForeName": "Shih-Chou", "Initials": "SC"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Singapore Eye Research Institute, Singapore National Eye Centre, 11 Third Hospital Avenue, Singapore, 168751, Singapore."}, {"Identifier": [], "Affiliation": "Duke-NUS Medical School, National University of Singapore, Singapore, Singapore."}], "LastName": "Yanagi", "ForeName": "Yasuo", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Osaka Metropolitan University Hospital, Osaka City, Osaka, Japan."}], "LastName": "Honda", "ForeName": "Shigeru", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Ophthalmology and Visual Sciences, Hong Kong Eye Hospital, 147K Argyle Street, Kowloon, Hong Kong."}], "LastName": "Lai", "ForeName": "Timothy Y Y", "Initials": "TYY"}, {"Identifier": ["0000-0003-3358-3516"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Singapore Eye Research Institute, Singapore National Eye Centre, 11 Third Hospital Avenue, Singapore, 168751, Singapore. gemmy.cheung.c.m@singhealth.com.sg."}, {"Identifier": [], "Affiliation": "Department of Ophthalmology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea. gemmy.cheung.c.m@singhealth.com.sg."}], "LastName": "Cheung", "ForeName": "Chui Ming Gemmy", "Initials": "CMG"}], "DataBankList": [{"DataBankName": "ClinicalTrials.gov", "AccessionNumberList": ["NCT01846273"]}], "GrantList": [{"GrantID": "NMRC/LCG/004/2018", "Agency": "National Medical Research Council Singapore Open Fund Large Collaborative Grant", "Country": ""}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "Ophthalmol Ther", "NlmUniqueID": "101634502"}, "CoiStatement": "Dr. Teo reports consultancy fees, honorarium, travel support and speaker fees from Bayer and Novartis outside the submitted work. Dr. Park reports consultancy fees, honorarium, travel support and speaker fees from Bayer, Novartis, Alcon, Roche, Samsug Bioepis, Oculight, RetiMark outside the submitted work. Dr. Ruamviboonsuk reports consultancy fees, grants, travel support and speaker fees from Roche and Bayer outside the submitted work. Dr Mori reports personal fees from Bayer Yakuhin Ltd., Chugai Pharmaceutical Co, Ltd., Novartis Pharma K.K., Senju Pharmaceutical Co, Ltd., Santen Pharmaceutical Co, Ltd, and Nippon Boehringer Ingelheim Co, Ltd. Dr. Chen SJ reports consultation fees from Roche, Bayer, Novartis and Allergan outside the submitted work. Dr. Lee reports consultancy fees, travel support and speaker fees from Bayer, Novartis, Roche outside the submitted work. Dr. Rajagopalan reports honorarium, grants and speaker fees from Alcon, Allergan, Bayer, Novartis and Roche outside the submitted work. Dr. Terasaki reports research support for instrument from Carl Zeiss and speaker fees from Alcon, Bayer, Novartis, Santen, Chugai and Sanofi outside the submitted work. Dr. Sekiryu reports support from Santen, Senju, Chugai, Alcon, Novartis, and Bayer outside the submitted work. Dr. Yanagi reports honorarium, grants and speaker fees from Alcon, Bayer, Boehringer Ingelheim, Kyowa Kirin, Novartis, Santen Pharmaceuticals, Senju Pharmaceuticals and Roche/Chugai outside the submitted work. Dr. Lai reports consultancy fees, grants, travel support and speaker fees from Bayer, Novartis and Roche during the conduct of the study; consultancy fees, grants and speaker fees from Bayer, Novartis and Roche outside the submitted work. Dr. Cheung reports consultancy fees, honorarium, travel support and speaker fees from Bayer, Novartis, Roche, Boehringer Ingelheim, Zeiss and Topcon outside the submitted work."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K, SEVEN-UP Study Group Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP) Ophthalmology. 2013;120(11):2292\u20132299. doi: 10.1016/j.ophtha.2013.03.046.", "ArticleIdList": ["10.1016/j.ophtha.2013.03.046", "23642856"]}, {"Citation": "Arnold JJ, Campain A, Barthelmes D, et al. Two-year outcomes of \"treat and extend\" intravitreal therapy for neovascular age-related macular degeneration. Ophthalmology. 2015;122(6):1212\u20131219. doi: 10.1016/j.ophtha.2015.02.009.", "ArticleIdList": ["10.1016/j.ophtha.2015.02.009", "25846847"]}, {"Citation": "Cheung CMG, Lai TYY, Teo K, et al. Polypoidal choroidal vasculopathy: consensus nomenclature and non-indocyanine green angiograph diagnostic criteria from the Asia-Pacific Ocular Imaging Society PCV Workgroup. Ophthalmology. 2021;128(3):443\u2013452. doi: 10.1016/j.ophtha.2020.08.006.", "ArticleIdList": ["10.1016/j.ophtha.2020.08.006", "32795496"]}, {"Citation": "Cheung CMG, Lai TYY, Ruamviboonsuk P, et al. Polypoidal choroidal vasculopathy: definition, pathogenesis, diagnosis, and management. Ophthalmology. 2018;125:708\u2013724. doi: 10.1016/j.ophtha.2017.11.019.", "ArticleIdList": ["10.1016/j.ophtha.2017.11.019", "29331556"]}, {"Citation": "Chaikitmongkol V, Cheung CMG, Koizumi H, Govindahar V, Chhablani J, Lai TYY. Latest developments in polypoidal choroidal vasculopathy: epidemiology, etiology, diagnosis, and treatment. Asia Pac J Ophthalmol (Phila) 2020;9(3):260\u2013268. doi: 10.1097/01.APO.0000656992.00746.48.", "ArticleIdList": ["10.1097/01.APO.0000656992.00746.48", "PMC7299215", "32332215"]}, {"Citation": "Koh A, Lai TYY, Takahashi K, et al. Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: a randomized clinical trial. JAMA Ophthalmol. 2017;135(11):1206\u20131213. doi: 10.1001/jamaophthalmol.2017.4030.", "ArticleIdList": ["10.1001/jamaophthalmol.2017.4030", "PMC5710379", "28983556"]}, {"Citation": "Lee WK, Iida T, Ogura Y, et al. Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET study: a randomized clinical trial. JAMA Ophthalmol. 2018;136(7):786\u2013793. doi: 10.1001/jamaophthalmol.2018.1804.", "ArticleIdList": ["10.1001/jamaophthalmol.2018.1804", "PMC6136040", "29801063"]}, {"Citation": "Lim TH, Lai TYY, Takahashi K, et al. Comparison of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: the EVEREST\u00a0II randomized clinical trial. JAMA Ophthalmol. 2020;138(9):935\u2013942. doi: 10.1001/jamaophthalmol.2020.2443.", "ArticleIdList": ["10.1001/jamaophthalmol.2020.2443", "PMC7366282", "32672800"]}, {"Citation": "Wong TY, Ogura Y, Lee WK, et al. Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy: 2-year results of the PLANET study. Am J Ophthalmol. 2019;204:80\u201389. doi: 10.1016/j.ajo.2019.02.027.", "ArticleIdList": ["10.1016/j.ajo.2019.02.027", "30849345"]}, {"Citation": "Kang HM, Kim YM, Koh HJ. Five-year follow-up results of photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2013;155(3):438\u2013447. doi: 10.1016/j.ajo.2012.09.020.", "ArticleIdList": ["10.1016/j.ajo.2012.09.020", "23218705"]}, {"Citation": "Kim JY, Son WY, Kim RY, Kim M, Park YG, Park YH. Recurrence and visual prognostic factors of polypoidal choroidal vasculopathy: 5-year results. Sci Rep. 2021;11(1):21572. doi: 10.1038/s41598-021-00904-4.", "ArticleIdList": ["10.1038/s41598-021-00904-4", "PMC8566467", "34732787"]}, {"Citation": "Chong Teo KY, Squirrell DM, Nguyen V, et al. A multicountry comparison of real-world management and outcomes of polypoidal choroidal vasculopathy: fight retinal blindness! Cohort Ophthalmol Retina. 2019;3(3):220\u2013229. doi: 10.1016/j.oret.2018.11.003.", "ArticleIdList": ["10.1016/j.oret.2018.11.003", "31014698"]}, {"Citation": "Cho SC, Cho J, Park KH, Woo SJ. Massive submacular haemorrhage in polypoidal choroidal vasculopathy versus typical neovascular age-related macular degeneration. Acta Ophthalmol. 2020 doi: 10.1111/aos.14676.", "ArticleIdList": ["10.1111/aos.14676", "33289345"]}, {"Citation": "Wong CW, Cheung CM, Mathur R, et al. Three-year results of polypoidal choroidal vasculopathy treated with photodynamic therapy: retrospective study and systematic review. Retina. 2015;35(8):1577\u20131593. doi: 10.1097/IAE.0000000000000499.", "ArticleIdList": ["10.1097/IAE.0000000000000499", "25719986"]}, {"Citation": "Ruamviboonsuk P, Cheung GCM, Chainakul M, et al. Updates on risk factors, diagnosis, and treatments of polypoidal choroidal vasculopathy. Asia Pac J Ophthalmol (Phila) 2023;12:184\u2013195. doi: 10.1097/APO.0000000000000573.", "ArticleIdList": ["10.1097/APO.0000000000000573", "36728294"]}, {"Citation": "Fenner BJ, Cheung CMG, Sim SS, et al. Evolving treatment paradigms for PCV. Eye (Lond) 2022;36(2):257\u2013265. doi: 10.1038/s41433-021-01688-7.", "ArticleIdList": ["10.1038/s41433-021-01688-7", "PMC8807588", "34262165"]}, {"Citation": "Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432\u20131444. doi: 10.1056/NEJMoa062655.", "ArticleIdList": ["10.1056/NEJMoa062655", "17021319"]}, {"Citation": "Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419\u20131431. doi: 10.1056/NEJMoa054481.", "ArticleIdList": ["10.1056/NEJMoa054481", "17021318"]}, {"Citation": "Singer MA, Awh CC, Sadda S, et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology. 2012;119(6):1175\u20131183. doi: 10.1016/j.ophtha.2011.12.016.", "ArticleIdList": ["10.1016/j.ophtha.2011.12.016", "22306121"]}], "ReferenceList": []}], "History": [{"Year": "2023", "Month": "11", "Day": "20"}, {"Year": "2024", "Month": "1", "Day": "11"}, {"Year": "2024", "Month": "2", "Day": "3", "Hour": "21", "Minute": "42"}, {"Year": "2024", "Month": "2", "Day": "3", "Hour": "21", "Minute": "41"}, {"Year": "2024", "Month": "2", "Day": "3", "Hour": "11", "Minute": "15"}, {"Year": "2024", "Month": "2", "Day": "3"}], "PublicationStatus": "ppublish", "ArticleIdList": ["38308746", "PMC10912383", "10.1007/s40123-024-00888-0", "10.1007/s40123-024-00888-0"]}}], "PubmedBookArticle": []}